Down‐regulation of miR‐200c attenuates AngII‐induced cardiac hypertrophy via targeting the MLCK‐mediated pathway

Shan Hu, Mian Cheng, Xin Guo, Shun Wang, Beilei Liu, Hong Jiang, Congxin Huang, Gang WuJournal of Cellular and Molecular Medicine 2019 · DOI

TL;DR

This study reveals that a microRNA called miR-200c plays a pro-hypertrophic role in the heart, exacerbating cardiac hypertrophy. By targeting and downregulating myosin light chain kinase (MLCK), miR-200c contributes to the development of this condition, suggesting that inhibiting miR-200c could be a novel therapeutic strategy for treating cardiac hypertrophy.

What Problem Does This Paper Address?

Cardiac hypertrophy (CH) is a significant pathological condition where the heart muscle enlarges in response to various stressors. While it can be adaptive (e.g., from exercise), pathological CH is maladaptive and can lead to heart failure. The underlying molecular mechanisms of pathological CH are complex, involving oxidative stress, apoptosis, and inflammation. MicroRNAs (miRNAs) are known regulators of gene expression and have been implicated in cardiovascular diseases, including CH. However, the specific role of miR-200c in CH and its precise molecular targets within the heart remained unclear. This paper aims to elucidate the role of miR-200c in Angiotensin II (AngII)-induced cardiac hypertrophy and identify its direct molecular target, hypothesizing that it involves the myosin light chain kinase (MLCK) pathway.

Methods

The researchers employed a multi-pronged approach combining in vivo and in vitro models.

  • Animal Model: Transverse abdominal aortic constriction (TAC) was performed on Sprague-Dawley rats to induce pressure-overload-induced cardiac hypertrophy.
  • Cell Culture Model: Neonatal rat cardiomyocytes (NCMs) were treated with Angiotensin II (AngII) to induce hypertrophy in vitro.
  • Molecular Techniques:
    • Quantitative Real-Time PCR (qRT-PCR): Used to measure the expression levels of miR-200c and hypertrophic marker genes (ANP, BNP, β-MHC).
  • Western Blotting: Employed to assess protein levels of key molecules, including MLCK, phosphorylated MLC2 (p-MLC2), and apoptosis-related proteins (Bax, cleaved caspase-3, Bcl-2).
  • Echocardiography: Performed on rats to evaluate cardiac function and structural changes (e.g., interventricular septal thickness, left ventricular posterior wall thickness, ejection fraction).
  • Histological Analysis: Hematoxylin and eosin (HE) staining was used to assess cardiomyocyte cross-sectional area (CSA).
  • Immunofluorescence Staining: Used for α-actinin staining to visualize cardiomyocytes and measure cell surface area.
  • Apoptosis Assays: FITC-Annexin V/PI staining followed by flow cytometry was used to quantify apoptotic and necrotic cells.
  • ROS Measurement: The 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) probe and fluorescence microscopy were used to detect reactive oxygen species (ROS) production. Malondialdehyde (MDA) content and superoxide dismutase (SOD) activity were also measured as markers of oxidative stress.
  • Luciferase Reporter Assay: This was a key technique to directly confirm the interaction between miR-200c and its predicted target, MLCK. Reporter vectors containing the wild-type or mutated 3'-UTR of MLCK were co-transfected with miR-200c mimics into HEK 293 cells.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • miR-200c is Pro-Hypertrophic: Contrary to some previous findings in other contexts, this study demonstrates that miR-200c promotes cardiac hypertrophy in the heart. This highlights the context-dependent nature of miRNA function.
  • MLCK as a Direct Target: The study provides strong evidence that MLCK is a direct molecular target of miR-200c. This is a significant finding, as it establishes a direct mechanistic link between the miRNA and a key protein involved in cardiac contractility and hypertrophy.
  • MLCK Pathway is Crucial: The findings suggest that miR-200c exerts its pro-hypertrophic effects, at least in part, by downregulating MLCK and its downstream signaling, including MLC2 phosphorylation. This implicates the MLCK pathway as a central mediator in miR-200c's role in CH.
  • miR-200c Influences Apoptosis and ROS: The study links miR-200c to the regulation of both apoptosis and reactive oxygen species (ROS) production in hypertrophic cardiomyocytes, further contributing to the pathological process.

Key Results

  • miR-200c Upregulation in CH: miR-200c expression was found to be significantly increased in the hearts of rats subjected to aortic banding (TAC) and in AngII-treated NCMs.
  • miR-200c Inhibition Attenuates CH: Transfection with a miR-200c inhibitor significantly reduced hypertrophic markers (ANP, BNP, β-MHC mRNA) and cardiomyocyte surface area in AngII-treated NCMs.
  • miR-200c Mimics Exacerbate CH: Conversely, overexpression of miR-200c using mimics worsened hypertrophy.
  • MLCK is Directly Targeted: Luciferase reporter assays showed that miR-200c significantly reduced the luciferase activity of a reporter containing the wild-type 3'-UTR of MLCK, but not a mutated version, confirming direct binding.
  • MLCK and p-MLC2 Levels Affected: miR-200c mimics decreased MLCK and p-MLC2 levels, while the inhibitor increased them in AngII-treated NCMs.
  • Apoptosis and ROS Modulation: miR-200c mimics increased apoptosis and ROS production, while the inhibitor reduced them in AngII-treated NCMs.
  • MLCK Inhibition Reverses miR-200c Inhibitor Effects: Treatment with an MLCK inhibitor (ML-7) partially reversed the protective effects of the miR-200c inhibitor on AngII-induced hypertrophy, further supporting the role of the MLCK pathway.

Limitations and Future Work

  • Context-Specific Role: The authors acknowledge that miR-200c's role as pro-hypertrophic is context-dependent, as it has been shown to have anti-cancer roles in other tissues.
  • Therapeutic Potential: The study suggests miR-200c as a potential therapeutic target, but further in vivo validation of therapeutic strategies targeting miR-200c is needed.
  • Broader Mechanisms: While MLCK is identified as a key target, other downstream effectors and regulatory pathways influenced by miR-200c in cardiac hypertrophy may exist and warrant further investigation.
  • Clinical Translation: The findings are based on animal and cell models, and translation to human clinical applications would require extensive further research.

Summary updated

Abstract

Our studies suggest that miR-200c may serve as a potential therapeutic target that could delay hypertrophy. We have also uncovered a relationship between miR-200c and MLCK, identifying MLCK as a direct mediator of miR-200c.
BibTeX
@article{hu2019downregulation,
  author = {Shan Hu and Mian Cheng and Xin Guo and Shun Wang and Beilei Liu and Hong Jiang and Congxin Huang and Gang Wu},
  title = {{Down‐regulation of miR‐200c attenuates AngII‐induced cardiac hypertrophy via targeting the MLCK‐mediated pathway}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2019},
  doi = {10.1111/jcmm.14135},
}
Figure